4 MENORAT HAMAOR ST., TEL AVIV, L3
Director Retirement - Paul Stuka Steps Down from InspireMD Board
Reports First Quarter 2026 Financial Results
Announces FDA Approval of Investigational Device Exemption for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD, Inc. Enters $75 Million Equity Distribution Agreement with BTIG
Reports Fourth Quarter and Full Year 2025 Financial Results
COO Departure - Andrea Tommasoli Dismissed from InspireMD, Inc.
Director Resignation - Kathryn Arnold Steps Down from InspireMD Board
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence